Syndax Pharmaceuticals (NASDAQ:SNDX) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX - Free Report) in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a $41.00 price target on the stock.

Several other analysts have also issued reports on SNDX. Scotiabank lowered shares of Syndax Pharmaceuticals from a sector outperform rating to a sector perform rating and decreased their price target for the stock from $36.00 to $23.00 in a research report on Wednesday, January 31st. StockNews.com upgraded shares of Syndax Pharmaceuticals to a sell rating in a research report on Friday, January 19th. Finally, JPMorgan Chase & Co. raised their price target on Syndax Pharmaceuticals from $31.00 to $34.00 and gave the company an overweight rating in a report on Wednesday, March 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average price target of $34.42.

Syndax Pharmaceuticals Stock Down 1.8 %

SNDX stock traded down $0.41 during trading hours on Thursday, hitting $21.97. The company's stock had a trading volume of 838,175 shares, compared to its average volume of 1,116,099. Syndax Pharmaceuticals has a 12 month low of $11.22 and a 12 month high of $25.34. The stock has a 50 day moving average price of $22.47 and a two-hundred day moving average price of $20.16. The company has a market capitalization of $1.87 billion, a PE ratio of -7.53 and a beta of 1.01.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $0.11. During the same period in the prior year, the company posted ($0.59) EPS. Sell-side analysts expect that Syndax Pharmaceuticals will post -3.74 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SNDX. China Universal Asset Management Co. Ltd. lifted its stake in Syndax Pharmaceuticals by 97.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,782 shares of the company's stock valued at $26,000 after purchasing an additional 880 shares during the last quarter. CWM LLC raised its position in Syndax Pharmaceuticals by 415.3% in the fourth quarter. CWM LLC now owns 1,685 shares of the company's stock valued at $36,000 after purchasing an additional 1,358 shares during the last quarter. MeadowBrook Investment Advisors LLC bought a new stake in shares of Syndax Pharmaceuticals during the fourth quarter worth about $37,000. Quadrant Capital Group LLC raised its holdings in Syndax Pharmaceuticals by 158.3% in the 4th quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company's stock valued at $53,000 after buying an additional 1,496 shares during the last quarter. Finally, Annandale Capital LLC bought a new stake in Syndax Pharmaceuticals during the 3rd quarter worth approximately $67,000.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).